Investigational drug · Phase 3
HR17031
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Adult Patients With Type 2 Diabetes, Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
7
Any phase or sponsor naming "HR17031"
First trial start
2024
Apr 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HR17031", any sponsor or status.
Conditions studied
As listed on its trial records.
- Adult Patients With Type 2 Diabetes
- Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HR17031" as an intervention, largest first.
- A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 DiabetesPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05333835 · 455 participants · Start Jul 8, 2022 · Primary completion Mar 30, 2024
Drug: HR17031 injection; INS068 injection and 1 more · For: Type 2 Diabetes
Sites: Beijing, China
- A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 DiabetesPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06881264 · 401 participants · Start Apr 30, 2024 · Primary completion Sep 19, 2025
Drug: HR17031 injection; insulin glargine · For: Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
Sites: Beijing, China
- A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 DiabetesPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06871761 · 393 participants · Start May 8, 2024 · Primary completion May 13, 2025
Drug: HR17031 injection; insulin glargine · For: Adult Patients With Type 2 Diabetes
Sites: Tianjin, China
- A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different SitesCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06086912 · 24 participants · Start Nov 7, 2023 · Primary completion Dec 12, 2023
Drug: HR17031; HR17031 and 1 more · For: Type 2 Diabetes
Sites: Beijing, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05031871 · 24 participants · Start Sep 2, 2021 · Primary completion Nov 19, 2021
Drug: HR17031 injection ;INS068 injection;SHR20004 injection; HR17031 injection ;INS068 injection;SHR20004 injection and 2 more · For: Type 2 Diabetes Mellitus
Sites: Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05292495 · 24 participants · Start Oct 12, 2022 · Primary completion Apr 10, 2024
Drug: HR17031 injection · For: Improved Glycemic Control in Patients With Type 2 Diabetes
Sites: Beijing, China
- A Trial of HR17031 Injection With Hepatic InsufficiencyStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05151705 · 24 participants (planned) · Start Dec 20, 2021 · Primary completion Jun 15, 2022
Drug: HR17031 injection; HR17031 injection and 1 more · For: Improved Glycemic Control in Patients With Type 2 Diabetes
Newest research
PubMed records naming it or its code names, newest first.
- Glycemic control and weight loss benefits of fixed-ratio combinations of basal insulins and GLP1 receptor agonists in type 2 diabetes: A systematic review and network meta-analysis.
Kamrul-Hasan ABM, Mondal S, Nagendra L, et al. · Endocrine 2026
- Pharmacokinetics and safety of HR17031, a fixed-ratio of INS068/Noiiglutide combination, in Chinese patients with hepatic impairment.
Wang D, Gao X, Mai J, et al. · Diabetes Obes Metab 2026
- Efficacy and safety benefits of HR17031, a fixed-ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open-label, randomised, parallel three-arm, treat-to-target trial.
Ji L, Huang D, Lin X, et al. · Diabetes Obes Metab 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.